This preprint is under consideration at Journal of Neuroinflammation. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Short report
Anti-NMDAR encephalitis induced in mice by active immunization with a peptide from amino-terminal domain of the GluN1 subunit
honghao wang
Nanfang Hospital, Southern Medical University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-1215-6219
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a recently discovered autoimmune syndrome associated with psychosis, dyskinesia, and seizures. However, the underlying mechanisms of this disease remain unclear, in part because of a lack of suitable animal models. This study describes a novel mouse model of anti-NMDAR encephalitis that was induced by active immunization against NMDARs using amino-terminal domain peptides. After 12 weeks of immunization, the mice showed significant behavioral disorders and memory loss. Furthermore, antibodies from the cerebrospinal fluid of immunized mice lowered the surface NMDAR cluster density in hippocampal neurons. Immunization also impaired long-term potentiation at Schaffer collateral–CA1 synapses and reduced NMDAR-induced calcium influx. This novel mouse model may allow further research into the pathogenesis of anti-NMDAR encephalitis and aid in the development of new therapies for this disease.
Keywords
Anti-NMDA receptor encephalitis, ATD, GluN1, active immunization, Cerebrospinal fluid
Figure 1
Figure 2
Figure 3
Figure 4
This is a list of supplementary files associated with this preprint. Click to download.
1 comment flagged for moderation
If you posted a comment and think it was mistakenly removed, please contact customer support at [email protected].
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 2
Posted 02 Jun, 2020
No community comments so far
Review #2 received
Received 21 Jun, 2020
Editorial decision: Major Revision
On 21 Jun, 2020
Review #1 received
Received 04 Jun, 2020
Reviewer #2 agreed
On 31 May, 2020
Reviewer #1 agreed
On 29 May, 2020
Reviewers invited
Invitations sent on 27 May, 2020
Editor assigned
On 26 May, 2020
Submission checks complete
On 25 May, 2020
Editor invited
On 25 May, 2020
No comments provided
Review #1 received
Received 02 Apr, 2020
Editorial decision: Major Revision
On 02 Apr, 2020
Review #2 received
Received 31 Mar, 2020
Reviewer #2 agreed
On 22 Mar, 2020
Reviewers invited
Invitations sent on 20 Mar, 2020
Reviewer #1 agreed
On 20 Mar, 2020
Editor assigned
On 12 Mar, 2020
First submitted
On 11 Mar, 2020
Submission checks complete
On 11 Mar, 2020
Editor invited
On 11 Mar, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Neurobiology of Disease
Learn more about our company.
This preprint is under consideration at Journal of Neuroinflammation. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Short report
Anti-NMDAR encephalitis induced in mice by active immunization with a peptide from amino-terminal domain of the GluN1 subunit
honghao wang
Nanfang Hospital, Southern Medical University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-1215-6219
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 2
Posted 02 Jun, 2020
No community comments so far
Review #2 received
Received 21 Jun, 2020
Editorial decision: Major Revision
On 21 Jun, 2020
Review #1 received
Received 04 Jun, 2020
Reviewer #2 agreed
On 31 May, 2020
Reviewer #1 agreed
On 29 May, 2020
Reviewers invited
Invitations sent on 27 May, 2020
Editor assigned
On 26 May, 2020
Submission checks complete
On 25 May, 2020
Editor invited
On 25 May, 2020
No comments provided
Review #1 received
Received 02 Apr, 2020
Editorial decision: Major Revision
On 02 Apr, 2020
Review #2 received
Received 31 Mar, 2020
Reviewer #2 agreed
On 22 Mar, 2020
Reviewers invited
Invitations sent on 20 Mar, 2020
Reviewer #1 agreed
On 20 Mar, 2020
Editor assigned
On 12 Mar, 2020
First submitted
On 11 Mar, 2020
Submission checks complete
On 11 Mar, 2020
Editor invited
On 11 Mar, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Neurobiology of Disease
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a recently discovered autoimmune syndrome associated with psychosis, dyskinesia, and seizures. However, the underlying mechanisms of this disease remain unclear, in part because of a lack of suitable animal models. This study describes a novel mouse model of anti-NMDAR encephalitis that was induced by active immunization against NMDARs using amino-terminal domain peptides. After 12 weeks of immunization, the mice showed significant behavioral disorders and memory loss. Furthermore, antibodies from the cerebrospinal fluid of immunized mice lowered the surface NMDAR cluster density in hippocampal neurons. Immunization also impaired long-term potentiation at Schaffer collateral–CA1 synapses and reduced NMDAR-induced calcium influx. This novel mouse model may allow further research into the pathogenesis of anti-NMDAR encephalitis and aid in the development of new therapies for this disease.
Figure 1
Figure 2
Figure 3
Figure 4